# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Insti...
ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure Rates First P...
Piper Sandler analyst Biren Amin initiates coverage on Allogene Therapeutics (NASDAQ:ALLO) with a Overweight rating and anno...
Oppenheimer analyst Mark Breidenbach maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and lowers the price ta...
HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price t...